Skip to main content

Table 2 Characteristics of study CHCs’ patients with diabetes as of May 30, 2014 (beginning of pre-intervention period)

From: Does increased implementation support improve community clinics’ guideline-concordant care? Results of a mixed methods, pragmatic comparative effectiveness trial

 

Arm 1 CHCs

Arm 2 CHCs

Arm 3 CHCs

Comparison CHCs

p value

N

(%)

N

(%)

N

(%)

N

(%)

Total patients

3849

 

5098

 

3370

 

33,638

 Indicated for statin use

3299

(85.7)

4239

(83.2)

2850

(84.6)

28,257

(84.0)

0.009

 Indicated for ACE/ARB use

2589

(67.3)

3580

(70.2)

2369

(70.3)

22,808

(67.8)

< 0.001

Age (years)

0.009

 18–21

31

(0.8)

33

(0.6)

24

(0.7)

212

(0.6)

 22 to 39

357

(9.3)

574

(11.3)

337

(10.0)

3649

(10.8)

 40 to 75

3169

(82.3)

4064

(79.7)

2744

(81.4)

27,309

(81.2)

 > 75

292

(7.6)

427

(8.4)

265

(7.9)

2468

(7.3)

Gender

< 0.001

 Female

2047

(53.2)

3057

(60.0)

1831

(54.3)

18,707

(55.6)

 Male

1802

(46.8)

2041

(40.0)

1539

(45.7)

14,931

(44.4)

Race/ethnicity

< 0.001

 Non-Hispanic White

2,417

(62.8)

880

(17.3)

2389

(70.9)

15,582

(46.3)

 Non-Hispanic Black

44

(1.1)

1364

(26.8)

196

(5.8)

7056

(21.0)

 Non-Hispanic Other

127

(3.3)

350

(6.9)

126

(3.7)

2134

(6.3)

 Hispanic

1249

(32.4)

2494

(48.9)

652

(19.3)

8734

(26.0)

 Unknown

12

(0.3)

10

(0.2)

7

(0.2)

132

(0.4)

Patient preferred language

< 0.001

 English

2781

(72.3)

3259

(63.9)

2883

(85.5)

23,979

(71.3)

 Spanish

993

(25.8)

1690

(33.2)

395

(11.7)

7011

(20.8)

 Other

46

(1.2)

138

(2.7)

79

(2.3)

2372

(7.1)

 Unknown

29

(0.8)

11

(0.2)

13

(0.4)

276

(0.8)

Household income as % of FPL*

< 0.001

 0 to 100%

1829

(47.5)

1456

(28.6)

1317

(39.1)

17,999

(53.5)

 101 to 200%

776

(20.2)

425

(8.3)

758

(22.5)

6393

(19.0)

 > 200%

122

(3.2)

62

(1.2)

287

(8.5)

2271

(6.8)

 Unknown

1122

(29.2)

3155

(61.9)

1008

(29.9)

6975

(20.7)

Insurance status*

< 0.001

 Medicaid

1421

(36.9)

1924

(37.7)

1089

(32.3)

11,436

(34.0)

 

 Medicare

1403

(36.5)

1725

(33.8)

1315

(39.0)

10,386

(30.9)

 

 Other public

41

(1.1)

8

(0.2)

23

(0.7)

742

(2.2)

 

 Private

397

(10.3)

400

(7.8)

504

(15.0)

3829

(11.4)

 

 Uninsured

587

(15.3)

1041

(20.4)

439

(13.0)

7245

(21.5)

 

LDL control (mg/dL)**

< 0.001

 Not in control (> 129 mg/dL)

512

(13.3)

733

(14.4)

482

(14.3)

5311

(15.8)

 In control (< = 129 mg/dL)

2643

(68.7)

3453

(67.7)

2373

(70.4)

22,888

(68.0)

 Unknown

694

(18.0)

912

(17.9)

515

(15.3)

5439

(16.2)

HbA1c control (%)**

< 0.001

 Not in control (> = 7)

2022

(52.5)

2547

(50.0)

1735

(51.5)

17,265

(51.3)

 In control (< 7)

1561

(40.6)

2020

(39.6)

1428

(42.4)

14,186

(42.2)

 Unknown

266

(6.9)

531

(10.4)

207

(6.1)

2187

(6.5)

Blood pressure control (mm Hg)**

< 0.001

 Not in control

910

(23.6)

1,174

(23.0)

702

(20.8)

8258

(24.5)

 In control (< 140/90:< 60 yo, < 150/90:> = 60 yo)

2939

(76.4)

3923

(77.0)

2668

(79.2)

25,355

(75.4)

 Unknown

-

-

1

(0.0)

-

-

25

(0.1)

  1. *Assessed at most recent office visit prior to snapshot date **Most recent record available prior to snapshot date. P values from chi-square test for general association
  2. ACE/ARB angiotensin-converting-enzyme inhibitor/Angiotensin II receptor blockers, CHC community health center, FPL Federal Poverty Level, HbA1c Hemoglobin A1c, LDL Low-density lipoprotein